175 related articles for article (PubMed ID: 32596609)
1. Identification of Sphingosine Kinase-1 Inhibitors from Bioactive Natural Products Targeting Cancer Therapy.
Jairajpuri DS; Mohammad T; Adhikari K; Gupta P; Hasan GM; Alajmi MF; Rehman MT; Hussain A; Hassan MI
ACS Omega; 2020 Jun; 5(24):14720-14729. PubMed ID: 32596609
[TBL] [Abstract][Full Text] [Related]
2. Virtual Screening Approach to Identify High-Affinity Inhibitors of Serum and Glucocorticoid-Regulated Kinase 1 among Bioactive Natural Products: Combined Molecular Docking and Simulation Studies.
Mohammad T; Siddiqui S; Shamsi A; Alajmi MF; Hussain A; Islam A; Ahmad F; Hassan MI
Molecules; 2020 Feb; 25(4):. PubMed ID: 32070031
[TBL] [Abstract][Full Text] [Related]
3. Discovering Gummadiol and Isoarboreol as potential inhibitors of sphingosine kinase 1: virtual screening and MD simulation studies.
Elasbali AM; Al-Soud WA; Alhassan HH; Mousa Elayyan AE; Kamal M; Alanazi H; Alharbi B; Alharethi SH; Mohamed BM
J Biomol Struct Dyn; 2023; 41(22):12789-12797. PubMed ID: 36644886
[TBL] [Abstract][Full Text] [Related]
4. Functional implications of pH-induced conformational changes in the Sphingosine kinase 1.
Gupta P; Khan FI; Roy S; Anwar S; Dahiya R; Alajmi MF; Hussain A; Rehman MT; Lai D; Hassan MI
Spectrochim Acta A Mol Biomol Spectrosc; 2020 Jan; 225():117453. PubMed ID: 31446356
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ellagic acid as an inhibitor of sphingosine kinase 1: A targeted approach towards anticancer therapy.
Gupta P; Mohammad T; Khan P; Alajmi MF; Hussain A; Rehman MT; Hassan MI
Biomed Pharmacother; 2019 Oct; 118():109245. PubMed ID: 31352240
[TBL] [Abstract][Full Text] [Related]
6. Investigating potential of cholic acid, syringic acid, and mangiferin as cancer therapeutics through sphingosine kinase 1 inhibition.
Shakeel I; Khan S; Roy S; Sherwani F; Ahmad SF; Sohal SS; Afzal M; Hassan MI
Int J Biol Macromol; 2023 Dec; 253(Pt 5):127036. PubMed ID: 37788733
[TBL] [Abstract][Full Text] [Related]
7. PF543-like compound, a promising sphingosine kinase 1 inhibitor: Structure-based virtual screening and molecular dynamic simulation approaches.
Shahwan M; Hassan N; Ashames A; Alrouji M; Alhumaydhi F; Al Abdulmonem W; Muhsinah AB; Furkan M; Khan RH; Shamsi A; Atiya A
Int J Biol Macromol; 2023 Aug; 245():125466. PubMed ID: 37348582
[TBL] [Abstract][Full Text] [Related]
8. Investigation of sphingosine kinase 1 inhibitory potential of cinchonine and colcemid targeting anticancer therapy.
Roy S; Khan S; Jairajpuri DS; Hussain A; Alajmi MF; Islam A; Luqman S; Parvez S; Hassan MI
J Biomol Struct Dyn; 2022 Sep; 40(14):6350-6362. PubMed ID: 33565370
[TBL] [Abstract][Full Text] [Related]
9. Identification and evaluation of bioactive natural products as potential inhibitors of human microtubule affinity-regulating kinase 4 (MARK4).
Mohammad T; Khan FI; Lobb KA; Islam A; Ahmad F; Hassan MI
J Biomol Struct Dyn; 2019 Apr; 37(7):1813-1829. PubMed ID: 29683402
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel modulators targeting human TRPC5: Docking-based virtual screening, molecular dynamics simulation and binding affinity predication.
Liu B; Zhang W; Guo S; Zuo Z
J Mol Graph Model; 2021 Jan; 102():107795. PubMed ID: 33161371
[TBL] [Abstract][Full Text] [Related]
11. Design and Development of Novel Urea, Sulfonyltriurea, and Sulfonamide Derivatives as Potential Inhibitors of
Roy S; Mahapatra AD; Mohammad T; Gupta P; Alajmi MF; Hussain A; Rehman MT; Datta B; Hassan MI
Pharmaceuticals (Basel); 2020 Jun; 13(6):. PubMed ID: 32526899
[TBL] [Abstract][Full Text] [Related]
12. Structure-based virtual screening and molecular dynamics simulation for the identification of sphingosine kinase-2 inhibitors as potential analgesics.
Akhilesh ; Baidya ATK; Uniyal A; Das B; Kumar R; Tiwari V
J Biomol Struct Dyn; 2022; 40(23):12472-12490. PubMed ID: 34519252
[TBL] [Abstract][Full Text] [Related]
13. Identifying novel sphingosine kinase 1 inhibitors as therapeutics against breast cancer.
Khan FI; Lai D; Anwer R; Azim I; Khan MKA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):172-186. PubMed ID: 31752564
[TBL] [Abstract][Full Text] [Related]
14. A High-Throughput Genetic Complementation Assay in Yeast Cells Identified Selective Inhibitors of Sphingosine Kinase 1 Not Found Using a Cell-Free Enzyme Assay.
Kashem MA; Kennedy CA; Fogarty KE; Dimock JR; Zhang Y; Sanville-Ross ML; Skow DJ; Brunette SR; Swantek JL; Hummel HS; Swindle J; Nelson RM
Assay Drug Dev Technol; 2016; 14(1):39-49. PubMed ID: 26426296
[TBL] [Abstract][Full Text] [Related]
15. Discovery of potential competitive inhibitors against With-No-Lysine kinase 1 for treating hypertension by virtual screening, inverse pharmacophore-based lead optimization, and molecular dynamics simulations.
Jonniya NA; Sk MF; Roy R; Kar P
SAR QSAR Environ Res; 2022 Feb; 33(2):63-87. PubMed ID: 35078380
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of sphingosine kinase 1 substrate recognition and catalysis.
Wang Z; Min X; Xiao SH; Johnstone S; Romanow W; Meininger D; Xu H; Liu J; Dai J; An S; Thibault S; Walker N
Structure; 2013 May; 21(5):798-809. PubMed ID: 23602659
[TBL] [Abstract][Full Text] [Related]
17. Identifying Isoononin and Candidissiol as Rho-associated protein kinase 1 (ROCK1) inhibitors: a combined virtual screening and MD simulation approach.
Alotaibi BS; Joshi J; Hasan MR; Khan MS; Alharethi SH; Mohammad T; Alhumaydhi FA; Elasbali AM; Hassan MI
J Biomol Struct Dyn; 2023; 41(14):6749-6758. PubMed ID: 35965440
[TBL] [Abstract][Full Text] [Related]
18. AP-1 regulates sphingosine kinase 1 expression in a positive feedback manner in glomerular mesangial cells exposed to high glucose.
Huang K; Huang J; Chen C; Hao J; Wang S; Huang J; Liu P; Huang H
Cell Signal; 2014 Mar; 26(3):629-38. PubMed ID: 24342046
[TBL] [Abstract][Full Text] [Related]
19. Identification of high-affinity inhibitors of pyruvate dehydrogenase kinase-3: towards therapeutic management of cancer.
Mohammad T; Arif K; Alajmi MF; Hussain A; Islam A; Rehman MT; Hassan I
J Biomol Struct Dyn; 2021 Feb; 39(2):586-594. PubMed ID: 31903847
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Potential of SphK1 Inhibitors Based on Abnormal Expression of SphK1 in Inflammatory Immune Related-Diseases.
Bu Y; Wu H; Deng R; Wang Y
Front Pharmacol; 2021; 12():733387. PubMed ID: 34737701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
